Targeting cellular senescence in progenitor cells as a strategy to enhance bone regeneration by cell therapies: a systematic review of pre-clinical investigations.

Mayu Morita, Eshan B Damle, Issei Shinohara, Masatoshi Murayama, Yosuke Susuki, Qi Gao, Chao Ma, Simon Kwoon-Ho Chow, Stuart Barry Goodman

Department of Orthopaedic Surgery, School of Medicine, Stanford University, Palo Alto, CA, USA.Department of Orthopaedic Surgery, School of Medicine, Stanford University, Palo Alto, CA, USA. · pubmed

Paper

Abstract

With the global population aging, optimizing bone regeneration is becoming increasingly important for enhancing the quality of life among elderly individuals. Progenitor cell-based therapies, such as mesenchymal stromal cells and induced pluripotent stem cells for bone regeneration have shown challenges due to cellular senescence and the control of the differentiation processes remain significant hurdles. In particular, elevated expression of senescence markers may play a pivotal role in limiting bone regeneration. This systematic review examines how these senescence markers influence the efficacy of progenitor cell therapies and whether targeting them could improve outcomes.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Targeting cellular senescence in progenitor cells could enhance bone regeneration outcomes. This paper is relevant as it addresses cellular senescence, a fundamental aspect of aging, and explores strategies to improve regenerative therapies, which could have implications for longevity and age-related decline in bone health.

Author of this paper? Send a correction.